#ASH24

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent...

3 months ago

The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏

#ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25

International community, share your throwbacks from past ASH meetings! #HemeSky

6 2 0 0

Chan Cheah

@chancheah.bsky.social

9 months ago

Fastest review I have ever been involved with - written almost entirely on the plane back from #ASH24
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

1 0 0 0

Society of Hematologic Oncology

10 months ago

Thanks to all the participants, speakers, and sponsors who made HOA LA possible!

Gracias a todos los participantes, ponentes y patrocinadores que hicieron posible este encuentro único en HOA LA.

#ASH24 #HighlightsOfASH #ASHLA #Hematología #Medicina #HemeSky #MedSKy

2 0 0 0

@societyofhemonc.bsky.social

10 months ago

SOHO Insider Emavusertib Shows Promise in High-Risk MDS Emavusertib yields remissions in high-risk MDS with spliceosome mutations, per ASH 2023 TakeAim trial data."

Preliminary TakeAim data shows promise of #emavusertib in higher-risk #MDS #ASH24 #ASHthrowback

sohoinsider.com/meetings-con...

0 0 0 0

@anand-88-patel.bsky.social

11 months ago

📅 Last call! Join ASH and Société Marocaine d'Hématologie for a practice-changing weekend!

Learn the clinical applications of groundbreaking #ASH24 research in a small-meeting, interactive environment where you can get all your questions answered:
bit.ly/4gQ2zQD

#HemeSKy #Hematology

0 0 0 0

Anand Patel

11 months ago

New paper in @bloodjournal.bsky.social by Wuliji et al on their work on social determinants & allo-HCT in AML! This was also a plenary at #ASH24

-SDOH are associated w/ access to transplant
-for those that get transplant those SDOH don't seem to impact survival

ashpublications.org/blood/articl...

2 0 0 0

11 months ago

🎥 Dr Ian Bouligny shares the results of a Phase II trial investigating ipilimumab, nivolumab, or ipilimumab + nivolumab with/without azacitidine in R/R MDS:

👉 buff.ly/m8zEtUu 👈

#ImmunoOnc #ASH24 #MDSsm #HemOnc #CTSM #TrialUpdate #BloodSky #Hemesky

1 0 0 0

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

1 year ago

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL @ASH_hematology #ASH24 #lymsm www.onclive.com/view/fixed-d...

0 0 0 0

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis The POIESIS trial is evaluating navtemadlin plus ruxolitinib in JAK inhibitor–naive patients with myelofibrosis with a suboptimal response to ruxolitinib.

1 year ago

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis @ash.hematology.org #ASH24 #hematology
www.onclive.com/view/navtema...

2 0 0 0

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

1 year ago

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS
@mdanderson.bsky.social @ash.hematology.org #ASH24 #lymsm #hematology
www.onclive.com/view/ivoside...

2 0 0 0

1 year ago

📢 Highlights of ASH® in Latin America | 25-26 abril | Punta del Este

🔬 Actualizaciones de la ASH Annual Meeting #ASH24
🩸 Sunset Session
📖 Meet & Greet con el Dr. Jorge Cortes
🍽 Lunch with the Experts

¡Inscríbete! 🔗 hematology.org/meetings/highlights/latin-america

#Hematología #Oncología

4 1 0 0

1 year ago

📢 Highlights of ASH® in Latin America | 25-26 abril | Punta del Este

🔬 Atualizações da ASH Annual Meeting #ASH24
🩸 Sunset Session
📖 Meet & Greet com Dr. Jorge Cortes
🍽 Lunch with the Experts

Garanta sua participação! 🔗 hematology.org/meetings/highlights/latin-america

#Hematologia #Oncologia

2 1 0 0

Combination Regimens Expand CLL Treatment Paradigm During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

1 year ago

Combination Regimens Expand CLL Treatment Paradigm @drmdavids.bsky.social @harvardmed.bsky.social @danafarber.bsky.social @kumedcenter.bsky.social @columbiacancer.bsky.social @ash.hematology.org #ASH24 #leusm #hematology
www.onclive.com/view/combina...

0 0 0 0

Mike Thompson, MD, PhD, FASCO

@mtmdphd.bsky.social

1 year ago

Paper: Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study [12/724] Cheruvalath et al. @MeeraMohanMD #ASH24 Abst 256 ash.confex.com/ash/2024/web... #mmsm #IDonc #SuppOnc HT @RahulBanerjeeMD

7 2 0 0

Mike Thompson, MD, PhD, FASCO

@mtmdphd.bsky.social

1 year ago

Paper: A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma [Dec 7, 2024] @EagleMyeloma et al. #ASH24 Abst 255
ash.confex.com/ash/2024/web... #mmsm #IDonc

3 0 0 0

1 year ago

5 razones para participar en el 2025 Highlights of ASH® in Latin America:
1️⃣ Actualizaciones de la ASH Annual Meeting
2️⃣ Lunch with the Experts
3️⃣ Networking con especialistas
4️⃣ Meet & Greet con el @jcortesmd.bsky.social
5️⃣ Sunset Session
Inscríbete👉 hematology.org/meeti...
#ASH24

3 0 0 0

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

1 year ago

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma @ash.hematology.org #ASH24 #mmsm #hematology
www.onclive.com/view/etentam...

0 0 0 0

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

1 year ago

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL @chunantes.bsky.social @ash.hematology.org #ASH24 #lymsm #hematology
www.onclive.com/view/ibrutin...

1 0 0 0

1 year ago

Had a chance to listen to our latest podcast?🎙️

👉Listen here: https://buff.ly/4bczFbp

Join Vaishali Sanchorawala and Ashutosh Wechalekar as they discuss the latest #amyloidosis updates, including:

⭐The #ANDROMEDA trial
⭐Risk stratification
⭐#MRD
⭐CAR-T

#HemOnc #ImmunoOnc #ASH24

0 0 0 0

1 year ago

2025 Highlights of ASH with Dr. Jorge Cortes YouTube video by American Society of Hematology

Stay ahead in hematology! 🚀 Watch our latest video with @jcortesmd.bsky.social to discover how Highlights of ASH brings groundbreaking research and clinical updates to you—wherever you are. 🩸🔬

🌍 Upcoming Global Events:
🇲🇦 Casablanca: Apr 4-5
🇺🇾 Punta del Este: Apr 25-26

#ASH24 #Hematology #HemeSky

8 0 0 0

1 year ago

Want the latest updates on #amyloidosis?🩸

🎧Listen to our podcast: https://buff.ly/3QrP9yn

Featuring Vaishali Sanchorawala & Ashutosh Wechalekar, who discuss:

👉The ANDROMEDA trial
👉Risk stratification
👉MRD
👉CAR-T therapies

#HemOnc #ASH24 #ImmunoOnc

0 0 0 0

1 year ago

Just weeks remain until #hematology professionals across the Mediterranean, Middle East, and North Africa region reunite over the most influential research from #ASH24 and discuss best practices for clinical application.

Plan to attend: bit.ly/4gQ2zQD

#BloodSky #HemeSKy

2 0 0 0

@targetedonc.bsky.social

1 year ago

#ASH24 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in #CLL.

www.targetedonc.com/view/highlig...

0 0 0 0

1 year ago

If you're interested in #SickleCellDisease, #Thalassemia, or #Hemophilia, don't miss out on our recent podcast episode!🎧🩸

Listen to key updates from leading experts on your favorite podcast platform:

👉 https://buff.ly/3EAYrWh 👈

#CTSM #ASH24 #TrialUpdate #Hematology

0 0 0 0

1 year ago

Almoce com especialistas e aprofunde-se nos principais temas da hematologia no 2025 Highlights of ASH® in Latin America.
✅ Escolha sua mesa e tema no 1º dia
✅ Participe de discussões interativas no 2º dia
🔗 Inscreva-se agora! 👉 hematology.org/meeti...

#ASH24 #Hematologia

2 0 0 0

@oncologyeducation.bsky.social

1 year ago

Almuerza con especialistas y profundiza en los principales temas de la hematología en el 2025 Highlights of ASH® in Latin America.

✅ Elige tu mesa y tema el 1º día
✅ Participa en discusiones interactivas el 2º día
🔗 ¡Inscríbete ahora! 👉 hematology.org/meeti...

#ASH24 #Hematología

1 0 0 0

OncologyEducation

1 year ago

The latest breakthroughs in #AML from #ASH24 are here! Oncology experts review the most impactful research, emerging therapies, and what these findings mean for clinical practice.
📹 Watch the full analysis: ow.ly/uFuS50V2ZrE

#OncEd #MedOnc

0 0 0 0